

BCMA-Targeted Immunotherapeutics in: October 2016 R&D and Business Tracker for Bispecific Antibodies

https://marketpublishers.com/r/B3232588A37EN.html

Date: November 2016 Pages: 21 Price: US\$ 225.00 (Single User License) ID: B3232588A37EN

Abstracts

BCMA-Targeted Immunotherapeutics in:

October 2016 R&D and Business Tracker for Bispecific Antibodies

This pdf report contains information about Bispecific Antibodies released during the month of October 2016. This issue forms part of the subscription service R&D and Business Tracker for Bispecific Antibodies.

Featured presentations of October 2016 include the pipeline of B-Cell Maturation Antigen (BCMA)-targeted immunotherapeutics, the profile of German technology company Pieris Pharmaceuticals and the bispecific technology profile of FIT-Ig from EpiMab.

The October 2016 issue of our R&D and Business Tracker service about Bispecific Antibodies covers;

T-Cell redirecting bispecific cancer antibodies

NK cell redirecting bispecific cancer antibodies

Bispecific immuno-oncology antibodies

Bispecific tumor antigens targeted cancer antibodies

Bispecific antibodies for inflammatory & autoimmune diseases



Bispecific antibodies for cardiometabolic, infectious, neurologic, ophthalmic or pulmonary diseases

The monthly update report about Bispecific Antibodies contains:

R&D and Technology Tracker

Pipeline changes

Regulatory news

Technology validations

Manufacturing news

Business Tracker for:

Company updates

Collaboration

Licensing

Merger & acquisitions

Financing

Clinical Trial Tracker

Scientific Publication Tracker

Featured Bispecific Technology Profile: FIT-Ig

Featured Company Profile: Pieris Pharmaceuticals

Featured Target or Technology Pipeline: BCMA-Targeted Immunotherapeutics

BCMA-Targeted Immunotherapeutics in: October 2016 R&D and Business Tracker for Bispecific Antibodies



BCMA-Targeted Immunotherapeutics include:

Autologous & allogeneic T-Cells

Bispecific tumor-targeted antibodies & T-cells

Bispecific T-Cell and NK-Cell redirecting antibodies

Antibody-Drug Conjugates

Information about the BCMA-Targeted Immunotherapeutics pipeline is provided in a tabular format and fully referenced.

Methodology:

Information released during the previous month is retrieved from a variety of sources including corporate press releases and statements, quarterly company business reports, SEC filings, company presentations, company websites, interviews, webcasts, journal articles, scientific abstracts and reviews, relevant scientific meetings, clinical trial databases, and La Merie Publishing's proprietary database. Relevant information is presented in textual and tabular formats with disclosure of scientific references or by a hyperlink leading to the source of information.

Customized Update Service:

The above described information service represents our standard module. At an incremental cost, the service can be exclusively widened and customized to specific client needs, e.g. preparation of a preferred presentation format, inclusion of a watch list for tracking, executive summary etc.



I would like to order

Product name: BCMA-Targeted Immunotherapeutics in: October 2016 R&D and Business Tracker for Bispecific Antibodies

Product link: https://marketpublishers.com/r/B3232588A37EN.html

Price: US\$ 225.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/B3232588A37EN.html</u>